Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
OrsoBio logo — Advancing first-in-class therapies to restore energy homeost...

OrsoBio

Advancing first-in-class therapies to restore energy homeostasis

Founded 2021 United States Palo Alto, United States 18 employees Series A Total: $62.30M Biopharma, Biotechnology +1

General Information

Company Name OrsoBio
Founded Year 2021
Location United States Palo Alto, United States
Founders / Decision Makers
Team member Team member
Employees 18
Industries Biopharma, Biotechnology, Health Care
Funding Stage Series A
Business Model B2B, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with OrsoBio. To contact OrsoBio, visit orsobio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OrsoBio compare?

A PDF of OrsoBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OrsoBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OrsoBio

OrsoBio, founded in 2021, is a United States-based, clinical-stage biopharmaceutical company aiming to transform the treatment of severe metabolic disorders. Guided by its slogan, "Advancing first-in-class therapies to restore energy homeostasis", the company focuses on innovative treatments for conditions such as type 2 diabetes and nonalcoholic steatohepatitis.

With four programs currently in clinical and preclinical development, OrsoBio is leveraging first-in-class compounds targeting central energy metabolism pathways, positioning itself at the cutting edge of the Biopharma, Biotechnology, and Health Care industries.

In a recent funding milestone, OrsoBio secured a $60.00M Series A investment on 07 November 2023. This significant backing from esteemed investors such as Longitude Capital, Eli Lilly, Enavate Sciences, Samsara BioCapital, and NuevaBio, underscores investor confidence in the company's mission and innovative approach.

Business keywords: first-in-class therapies, energy homeostasis, metabolic disorders, type 2 diabetes, severe dyslipidemias, lipodystrophies, nonalcoholic steatohepatitis, clinical-stage biopharmaceutical, energy metabolism pathways, therapeutics development, restoring energy balance, underlying cause treatment, severe metabolic conditions, private healthcare innovation, biopharmaceutical research

Services & Products

Developing first-in-class therapies
Targeting energy metabolism pathways
Restoring energy homeostasis

Target Customers

Patients with severe metabolic disorders Individuals with obesity and diabetes Healthcare providers focused on metabolic health

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $60.00M 5
Longitude Capital Eli Lilly Enavate Sciences
Longitude Capital, Eli Lilly +3
07 Nov 2023
Grant $2.30M 1
National Institute of Diabetes and Digestive and Kidney Diseases
02 Nov 2022

OrsoBio Alternatives & Competitors

View All Alternatives
OrsoBio vs
AusperBio
AusperBio United States

Transforming Patient Lives For a Better Tomorrow

Series B
8 employees
Biopharma, Biotechnology
OrsoBio vs
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals United States

Madrigal is focused on delivering novel therapeutics for MASH, a serious liver disease.

IPO
1129 employees
Biopharma, Biotechnology
OrsoBio vs
BioAge Labs
BioAge Labs United States

We are harnessing the biology of human aging to develop novel targets and therapies for metabolic di...

Series D
99 employees
Biopharma, Biotechnology
View all alternatives

FAQ About OrsoBio

Advancing first-in-class therapies to restore energy homeostasis
OrsoBio was founded in 2021.
OrsoBio is headquartered in Palo Alto, United States.
OrsoBio operates in Biopharma, Biotechnology and Health Care. Its work centres on first-in-class therapies, energy homeostasis, metabolic disorders and type 2 diabetes. Its customers include Patients with severe metabolic disorders, Individuals with obesity and diabetes and Healthcare providers focused on metabolic health.
OrsoBio has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.
OrsoBio has approximately 18 employees.
OrsoBio has completed 2 funding rounds, raising a total of $62.30M. The latest funding stage is Series A.
OrsoBio offers: Developing first-in-class therapies, Targeting energy metabolism pathways, Restoring energy homeostasis.
Top alternatives and competitors to OrsoBio include AusperBio, Madrigal Pharmaceuticals, BioAge Labs, Glyscend Therapeutics, Intellia Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OrsoBio and AusperBio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OrsoBio, https://bouncewatch.com/company/orsobio, updated 19 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout